CAMBRIDGE, Mass., Sept. 6, 2016 /CNW/ -- Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced today that Ankit Mahadevia, President and CEO, will participate in the Emerging Innovative Private Companies Panel at Citi's 11th Annual Biotech Conference in Boston, MA on Thursday, September 8, 2016 at 9:00am ET.
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a product-focused biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The company's pipeline of anti-infective agents is one of the most unique in the industry. The Spero Potentiator program provides the opportunity to increase the power of standard of care by enhancing existing drugs through a dramatic increase in their potency against multi-drug resistant gram-negative bacteria. The DHFR program is exploring a new approach to combatting drug resistance through expansion of a novel antifolate's antibacterial spectrum to treat trimethoprim resistant Gram-negative bacteria.
Spero's pipeline of drug candidates may uniquely reduce the morbidity caused by severe infections and promote their clearance, including in bacterial strains highly resistant to even the most potent existing antibiotics. Spero has recently joined international companies to call on governments and their industry to take comprehensive action against drug-resistant infections with a joint Declaration launched at the World Economic Forum in Davos, Switzerland. This statement sets out for the first time how governments and industry need to work with one another to support sustained investment in the new products needed to beat the challenges of rising drug resistance. For more information, please visit www.sperotherapeutics.com.
SOURCE Spero Therapeutics
For further information: Spectrum Science Communications: Maia Arnold, PhD, Senior Scientific Executive, 202-955-6222 x2506, firstname.lastname@example.org; INVESTOR CONTACT: Stern Investor Relations, Beth DelGiacco, Vice President, 212-362-1200, Beth@sternir.com, http://www.sperotherapeutics.com